Combined impact of myosteatosis and liver steatosis on prognosis in stage I–III colorectal cancer patients
Journal of Cachexia, Sarcopenia and Muscle · 2023-12 · 14 (6) · 2908-2915
DOI: 10.1002/jcsm.13369 ↗Kurz gefasst
Fachartikel in der Zeitschrift Journal of Cachexia, Sarcopenia and Muscle, online erschienen am 15.11.2023. Verfasst von Dong Hee Lee und 3 weiteren Autor:innen. Beteiligte Einrichtung: Department of Surgery, Gangnam Severance Hospital, Yonsei University College of Medicine, Seoul, Republic of Korea. Hauptthemen laut MEDLINE: Colorectal Neoplasms, Fatty Liver. Die Arbeit wurde bisher 12-mal zitiert (Crossref) und nennt 27 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0). Gefördert von: National Research Foundation of Korea (NRF).
Themen: Onkologische Pflege
Abstract (Originalsprache)
Background
Myosteatosis and liver steatosis (LS) have been recognized as patient‐derived image biomarkers that correlate with prognosis in colorectal cancer (CRC) patients. However, the significance of considering fat deposition in multiple body areas simultaneously has been underestimated. This study aimed to investigate the combined effect of myosteatosis and LS in stage I‐III CRC patients.
Methods
A total of 616 stage I‐III CRC patients were included in the study. Myosteatosis was assessed using skeletal muscle radiodensity (SMD), and LS was estimated by calculating the Hounsfield unit of the liver and spleen ratio (LSR). Cox proportional hazard models were utilized to evaluate disease‐free survival (DFS). A combination of myosteatosis and LS was proposed, and its discriminatory performance was compared using the C‐index.
Results
Among the 616 participants, the median (interquartile) age was 64 (55–72) years, and 240 (38.9%) were female. The median and interquartile range of LSR were determined as 1.106 (0.967–1.225). The optimal cutoff value for LSR was identified as 1.181, leading to the classification of patients into low (410, 66.5%) and high LSR (206, 33.4%) groups. Among the patients, 200 were categorized into the low SMD group, while 416 were allocated to the high SMD group. Both myosteatosis and LS were identified as independent prognostic factors in the multivariable analysis. The combination of these two variables resulted in a three‐group classification: high SMD with low LSR group, high SMD with high LSR group, and low SMD group. When comparing the C‐index values, the three‐group classification exhibited superior discriminatory performance compared with considering myosteatosis and LS separately.
Conclusions
Myosteatosis was associated with poorer survival, while the presence of LS was linked to a better prognosis in non‐metastatic CRC patients. Simultaneously considering fat infiltration can serve as a more effective prognosticator in non‐metastatic CRC patients.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Department of Surgery, Gangnam Severance Hospital, Yonsei University College of Medicine, Seoul, Republic of Korea.
- Biostatistics Collaboration Unit, Yonsei University College of Medicine, Seoul, Republic of Korea.
ORCID-Profile: Jeonghyun Kang
Förderung
- National Research Foundation of Korea (NRF)
Zitieren
APA
Lee, D. H., Jo, I., Lee, H. S., & Kang, J. (2023). Combined impact of myosteatosis and liver steatosis on prognosis in stage I–III colorectal cancer patients. Journal of Cachexia, Sarcopenia and Muscle, 14(6), 2908-2915. https://doi.org/10.1002/jcsm.13369
Vancouver
Lee DH, Jo I, Lee HS, Kang J. Combined impact of myosteatosis and liver steatosis on prognosis in stage I–III colorectal cancer patients. Journal of Cachexia, Sarcopenia and Muscle. 2023;14(6):2908-2915. doi:10.1002/jcsm.13369
BibTeX
@article{Lee2023,
author = {Lee, Dong Hee and Jo, Il and Lee, Hye Sun and Kang, Jeonghyun},
title = {Combined impact of myosteatosis and liver steatosis on prognosis in stage I–III colorectal cancer patients},
journal = {Journal of Cachexia, Sarcopenia and Muscle},
year = {2023},
volume = {14},
number = {6},
pages = {2908--2915},
doi = {10.1002/jcsm.13369}
}
EUVIMED